Abstract:OBJECTIVE For the past few years,the checkpoint inhibitors,such as PD-1 inhibitors and CTLA-4 in-hibitors,demonstrated an advantage in terms of the survival of melanoma and lung cancer patients with the development of novel immunotherapy agents.Thus,exploring predictive biomarkers may contribute to the screening the target population for immune checkpoint inhibitors and promoting the development of individualized precision therapy in advanced cancer. This article induced the progress about the predictive biomarkers of checkpoint inhibitors,providing a theoretical basis for the precision medicine study of immunotherapy.METHODS Based on Pubmed and CNKI database,by using "immune checkpoint inhibitors,biomarker,prognosis"as key words to trace related papers from 1995-10 to 2017-02.Inclusion crite-ria were as follows:the definition of immune checkpoint inhibitors;the mechanism of immune checkpoint inhibitors;the predictive factors of immune checkpoint inhibitors.Exclusion criteria:(1)Those exists problems in research designs or sta-tistical methods.(2)those has incomplete data or unclear results.Totally 44 papers (2 chinese literatures)were finally in-cluded for analysis.RESULTS The immune checkpoint inhibitors work specifically on the body's immune system to en-hance the antitumor activity of various immune cells.It is relatively slower to take effects.However,once the effects ap-pear,it will last for a very long period.Selecting the appropriate predictive factors and screening the target population be-fore the treatment plays a very important role for clinical choice.It has been proved that the expression rate of PD-L1,mi-crosatellite instability and tumor mutation burden are correlated with the treatment effects of immune checkpoint inhibi-tors.The significance of other biomarkers need further investigation.CONCLUSION The expression rate of PD-L1, microsatellite instability and tumor mutation burden were reliable predictive biomarkers for the treatment effects of im-mune checkpoint inhibitors.

Predictive Biomarkers for Tumor Immune Checkpoint Blockade

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

Predictive biomarkers for checkpoint blockade-based immunotherapy

Progresses in biomarkers for cancer immunotherapy

Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy

Advances and prospects of biomarkers for immune checkpoint inhibitors

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade

The development of biomarkers for cancer immunotherapy

Predictive Biomarkers for Cancer Immunotherapy with Immune Checkpoint Inhibitors

Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1

Immune checkpoint inhibitors: recent progress and potential biomarkers

Mechanistic Insight of Predictive Biomarkers for Antitumor PD‑1/PD‑L1 Blockade: A Paradigm Shift Towards Immunome Evaluation (Review)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

Predictive markers of immune checkpoint inhibitors

Predictive biomarkers in tumor treatment by blocking PD-1/PD-L1 pathway

Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors